Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Shares Outstanding (2016 - 2025)

Historic Shares Outstanding for Viking Therapeutics (VKTX) over the last 12 years, with Q3 2025 value amounting to $112.4 million.

  • Viking Therapeutics' Shares Outstanding rose 90.83% to $112.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $112.4 million, marking a year-over-year increase of 90.83%. This contributed to the annual value of $111.6 million for FY2024, which is 1144.67% up from last year.
  • Latest data reveals that Viking Therapeutics reported Shares Outstanding of $112.4 million as of Q3 2025, which was up 90.83% from $112.3 million recorded in Q2 2025.
  • Viking Therapeutics' 5-year Shares Outstanding high stood at $112.4 million for Q3 2025, and its period low was $76.7 million during Q2 2022.
  • Over the past 5 years, Viking Therapeutics' median Shares Outstanding value was $100.0 million (recorded in 2023), while the average stood at $93.8 million.
  • As far as peak fluctuations go, Viking Therapeutics' Shares Outstanding plummeted by 197.66% in 2022, and later surged by 3896.89% in 2024.
  • Over the past 5 years, Viking Therapeutics' Shares Outstanding (Quarter) stood at $78.2 million in 2021, then increased by 0.01% to $78.3 million in 2022, then rose by 27.93% to $100.1 million in 2023, then rose by 11.45% to $111.6 million in 2024, then grew by 0.78% to $112.4 million in 2025.
  • Its Shares Outstanding was $112.4 million in Q3 2025, compared to $112.3 million in Q2 2025 and $112.3 million in Q1 2025.